We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Purinergic (P2Y) Receptors

P2Y receptor antagonists and agonists act on purinergic G protein-coupled receptors for extracellular nucleotides. The eight human P2Y receptors respond to adenosine diphosphate (ADP), adenosine triphosphate (ATP), uridine triphosphate (UTP) or related nucleotides. The first member, now called P2Y1, was cloned from chick brain in 1993 as a G protein-coupled ATP receptor. In 2001 the platelet ADP receptor P2Y12 was identified as the target of thienopyridine antithrombotic compounds. Clopidogrel hydrogen sulfate and prasugrel are thienopyridine prodrugs, whereas ticagrelor, cangrelor and AZD1283 block P2Y12 without metabolic activation. BPTU is an allosteric P2Y1 antagonist, and MRS 2578 blocks P2Y6, a receptor activated by uridine diphosphate. Ligand-gated nucleotide channels are listed separately under the sibling category P2X Receptor.

1 Item

  • 5'-TMPS
    Cat. No.
    A62908
    CAS No.
    15548-51-3

    5'-TMPS

    Synonyms: Thymidine-5'-O-monophosphorothioate

    5'-TMPS (Thymidine-5'-O-monophosphorothioate) selectively targets P2Y6 receptors as a partial agonist while antagonizing P2Y14 receptors. This compound functions as a positive regulator of angiogenesis, demonstrating pro-angiogenic effects that may be leveraged in vascular research and related therapeutic applications. Its unique properties make it a valuable tool for studying the modulation of angiogenic processes in various biological contexts.

    In stock View Details
    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...